{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:19:57Z","timestamp":1767705597953},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1756-0500-7-459","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T05:03:36Z","timestamp":1405659816000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors\/serotonin\u2013norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study"],"prefix":"10.1186","volume":"7","author":[{"given":"Anita H","family":"Clayton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A","family":"Baker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary J","family":"Cain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina Vogel","family":"Marler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert M","family":"Berman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E","family":"Thase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,7,18]]},"reference":[{"key":"3010_CR1","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002, 302: 381-389.","journal-title":"J Pharmacol Exp Ther"},{"key":"3010_CR2","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","volume":"28","author":"DA Shapiro","year":"2003","unstructured":"Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol. 2003, 28: 1400-1411.","journal-title":"Neuropsychopharmacol"},{"key":"3010_CR3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejphar.2003.10.025","volume":"483","author":"S Jordan","year":"2004","unstructured":"Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA: In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol. 2004, 483: 45-53.","journal-title":"Eur J Pharmacol"},{"key":"3010_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0014-2999(02)01532-7","volume":"441","author":"S Jordan","year":"2002","unstructured":"Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA: The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol. 2002, 441: 137-140.","journal-title":"Eur J Pharmacol"},{"key":"3010_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2008.09.008","volume":"597","author":"Y Tadori","year":"2008","unstructured":"Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization of aripiprazole partial agonist activity at human dopamine D(3) receptors. Eur J Pharmacol. 2008, 597: 27-33.","journal-title":"Eur J Pharmacol"},{"key":"3010_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.4088\/JCP.v68n0604","volume":"68","author":"RM Berman","year":"2007","unstructured":"Berman RM, Marcus RN, Swanink R, McQuade RD, Carson WH, Corey-Lisle PK, Khan A: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007, 68: 843-853.","journal-title":"J Clin Psychiatry"},{"key":"3010_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1097\/JCP.0b013e31816774f9","volume":"28","author":"RN Marcus","year":"2008","unstructured":"Marcus RN, McQuade RD, Carson WH, Hennicken D, Fava M, Simon JS, Trivedi MH, Thase ME, Berman RM: The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008, 28: 156-165.","journal-title":"J Clin Psychopharmacol"},{"key":"3010_CR8","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1017\/S1092852900020216","volume":"14","author":"R Berman","year":"2009","unstructured":"Berman R, Fava M, Thase M, Swanink R, McQuade R, Carson W, Adson D, Taylor L, Hazel J, Marcus R: Aripiprazole augmentation in major depression: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectrums. 2009, 14: 197-206.","journal-title":"CNS Spectrums"},{"key":"3010_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2147\/NDT.S18333","volume":"7","author":"RM Berman","year":"2011","unstructured":"Berman RM, Thase ME, Trivedi MH, Hazel JA, Marler SV, McQuade RD, Carson W, Baker RA, Marcus RN: Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder. Neuropsychiatr Dis Treat. 2011, 7: 303-312.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3010_CR10","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4088\/PCC.v07n0305","volume":"7","author":"M Fava","year":"2005","unstructured":"Fava M, Rush AJ, Thase ME, Clayton A, Stahl SM, Pradko JF, Johnston JA: 15\u00a0years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Prim Care Companion J Clin Psychiatry. 2005, 7: 106-113.","journal-title":"Prim Care Companion J Clin Psychiatry"},{"key":"3010_CR11","volume-title":"Practice Guideline for the Treatment of Patients with Major Depressive Disorder","author":"American Psychiatric Association","year":"2010","unstructured":"American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder. 2010, American Psychiatric Publishing: Third edition"},{"issue":"Suppl 6","key":"3010_CR12","first-page":"33","volume":"67","author":"AH Clayton","year":"2006","unstructured":"Clayton AH, Montejo AL: Major depressive disorder, antidepressants, and sexual dysfunction. J Clin Psychiatry. 2006, 67 (Suppl 6): 33-37.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl 3","key":"3010_CR13","first-page":"5","volume":"62","author":"AH Clayton","year":"2001","unstructured":"Clayton AH: Recognition and assessment of sexual dysfunction associated with depression. J Clin Psychiatry. 2001, 62 (Suppl 3): 5-9.","journal-title":"J Clin Psychiatry"},{"key":"3010_CR14","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2165\/00023210-200822070-00006","volume":"22","author":"S Dhillon","year":"2008","unstructured":"Dhillon S, Yang LP, Curran MP: Spotlight on bupropion in major depressive disorder. CNS Drugs. 2008, 22: 613-617.","journal-title":"CNS Drugs"},{"key":"3010_CR15","doi-asserted-by":"publisher","first-page":"974","DOI":"10.4088\/JCP.v66n0803","volume":"66","author":"ME Thase","year":"2005","unstructured":"Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y: Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005, 66: 974-981.","journal-title":"J Clin Psychiatry"},{"key":"3010_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4088\/JCP.v63n0414","volume":"63","author":"AH Clayton","year":"2002","unstructured":"Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A: Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002, 63: 357-366.","journal-title":"J Clin Psychiatry"},{"issue":"Suppl E1","key":"3010_CR17","doi-asserted-by":"publisher","first-page":"e03","DOI":"10.4088\/JCP.9058se1c.03gry","volume":"71","author":"GI Papakostas","year":"2010","unstructured":"Papakostas GI: The efficacy, tolerability, and safety of contemporary antidepressants. J Clin Psychiatry. 2010, 71 (Suppl E1): e03-","journal-title":"J Clin Psychiatry"},{"key":"3010_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1177\/0269881111431748","volume":"26","author":"TE Schlaepfer","year":"2012","unstructured":"Schlaepfer TE, Agren H, Monteleone P, Gasto C, Pitchot W, Rouillon F, Nutt DJ, Kasper S: The hidden third: improving outcome in treatment-resistant depression. J Psychopharmacol. 2012, 26: 587-602.","journal-title":"J Psychopharmacol"},{"key":"3010_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1017\/S0033291711001905","volume":"42","author":"R Uher","year":"2012","unstructured":"Uher R, Perlis RH, Henigsberg N, Zobel A, Rietschel M, Mors O, Hauser J, Dernovsek MZ, Souery D, Bajs M, Maier W, Aitchison KJ, Farmer A, McGuffin P: Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms. Psychol Med. 2012, 42: 967-980.","journal-title":"Psychol Med"},{"key":"3010_CR20","unstructured":"Adjunctive antipsychotics for major depression. Med Lett Drugs Ther. 2011, 53: 74-75."},{"key":"3010_CR21","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S0193-953X(02)00107-7","volume":"26","author":"M Fava","year":"2003","unstructured":"Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ: Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003, 26: 457-494. x","journal-title":"Psychiatr Clin North Am"},{"key":"3010_CR22","first-page":"218","volume-title":"ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare Publication (ADM) 76\u2013338","author":"W Guy","year":"1976","unstructured":"Guy W: Clinical Global Impressions (CGI). ECDEU Assessment Manual for Psychopharmacology US Department of Health, Education, and Welfare Publication (ADM) 76\u2013338. 1976, Rockville, MD: National Institute of Mental Health, 218-222."},{"key":"3010_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000056257","volume":"70","author":"LA Labbate","year":"2001","unstructured":"Labbate LA, Lare SB: Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital Sexual Functioning Questionnaire. Psychother Psychosom. 2001, 70: 221-225.","journal-title":"Psychother Psychosom"},{"key":"3010_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/CVM-1-1-025","volume":"1","author":"P Sleight","year":"2000","unstructured":"Sleight P: Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!. Curr Control Trials Cardiovasc Med. 2000, 1: 25-27.","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"1","key":"3010_CR25","first-page":"PCC.10m00994","volume":"13","author":"M Fava","year":"2011","unstructured":"Fava M, Dording CM, Baker RA, Mankoski R, Tran QV, Forbes RA, Eudicone JM, Owen R, Berman RM: Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies. Prim Care Companion CNS Disord. 2011, 13 (1): PCC.10m00994-","journal-title":"Prim Care Companion CNS Disord"},{"key":"3010_CR26","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1345\/aph.1K630","volume":"42","author":"KN Sokolski","year":"2008","unstructured":"Sokolski KN: Adjunctive aripiprazole for bupropion-resistant major depression. Ann Pharmacother. 2008, 42: 1124-1129.","journal-title":"Ann Pharmacother"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-7-459.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T22:25:51Z","timestamp":1548195951000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-7-459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,18]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3010"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-7-459","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,18]]},"assertion":[{"value":"6 May 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"459"}}